newsfilter
← Earnings
Earnings Releases·

Cabaletta Bio — Third Quarter 2026 Earnings Summary

Cabaletta Bio reported third-quarter 2026 financial results showing research and development expenses of $47.1 million and a cash position of $299.4 million as of September 30, 2026. The company anticipates registrational topline results for its RESET-Myositis study in the second half of 2027, supporting a planned Biologics License Application submission in the first quarter of 2028. Additionally, the registrational cohort for systemic sclerosis has been initiated, and the company is advancing preconditioning-free trials to inform future development strategies. Cabaletta expects its current cash reserves to fund operations through the first quarter of 2028.

Company
CABALETTA BIO INC
Sector
Healthcare
Industry
Biotechnology